Calidi Biotherapeutics Stock Fundamentals
| CLDI Stock | 1.44 0.08 5.26% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Calidi Biotherapeutics' long-term financial health and intrinsic value.
As of now, Calidi Biotherapeutics' Selling And Marketing Expenses is decreasing as compared to previous years. Calidi | Select Account or Indicator | Build AI portfolio with Calidi Stock |
Calidi Biotherapeutics Company Shares Owned By Insiders Analysis
Calidi Biotherapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Calidi Biotherapeutics Shares Owned By Insiders | 20.13 % |
Most of Calidi Biotherapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calidi Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Calidi Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Calidi Biotherapeutics is extremely important. It helps to project a fair market value of Calidi Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Calidi Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Calidi Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Calidi Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 20.12599999999999% of Calidi Biotherapeutics are shares owned by insiders. This is 32.58% higher than that of the Biotechnology sector and 41.93% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 99.46% lower than that of the firm.
Calidi Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Calidi Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Calidi Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Calidi Biotherapeutics competition to find correlations between indicators driving Calidi Biotherapeutics's intrinsic value. More Info.Calidi Biotherapeutics is rated below average in return on asset category among its peers. It is rated fourth in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Calidi Biotherapeutics' earnings, one of the primary drivers of an investment's value.Calidi Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calidi Biotherapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calidi Biotherapeutics could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics of similar companies.Calidi Biotherapeutics is currently under evaluation in shares owned by insiders category among its peers.
Calidi Fundamentals
| Return On Asset | -1.58 | ||||
| Current Valuation | 7.08 M | ||||
| Shares Outstanding | 5.35 M | ||||
| Shares Owned By Insiders | 20.13 % | ||||
| Shares Owned By Institutions | 4.10 % | ||||
| Number Of Shares Shorted | 265.55 K | ||||
| Price To Book | 4.73 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (21.78 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.58 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Short Ratio | 1.58 X | ||||
| Earnings Per Share | (0.20) X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 7.7 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
| Net Asset | 14.18 M |
About Calidi Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calidi Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calidi Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calidi Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -4.6 M | -4.4 M | |
| Cost Of Revenue | 1.5 M | 1.6 M | |
| Stock Based Compensation To Revenue | 122.86 | 129.00 | |
| Sales General And Administrative To Revenue | 318.04 | 333.94 | |
| Research And Ddevelopement To Revenue | 145.14 | 152.40 | |
| Capex To Revenue | 8.56 | 8.99 | |
| Revenue Per Share | 0.73 | 1.39 | |
| Ebit Per Revenue | (591.05) | (561.50) |
Currently Active Assets on Macroaxis
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:Check out Calidi Biotherapeutics Piotroski F Score and Calidi Biotherapeutics Altman Z Score analysis. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.